The Study of Different Dose Rituximab in the Treatment of ITP

Status Completed

Clinical Trial Summary

The project was undertaking by Qilu Hospital of Shandong University in China. In order to compare the efficacy, safety and response duration of different dose of rituximab in patients primary immune thrombocytopenia(pITP).

Clinical Trial Description

62 patients with pITP who had failed to respond to glucocorticosteroids were randomly divided into 2 groups: group A(n = 32) and group B(n = 30). In group A, Rituximab was given with a fixed dose of 100 mg administered as an intravenous infusion weekly (on day 1, 8, 15 and 22). In group B, Rituximab was given with a single dose of 375mg/m2. The clinical effect, onset time, duration of efficacy and adverse reactions were observed to compare the efficacy and safety of two different plans. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03258866
Study type	Interventional
Source	Shandong University
Contact
Status	Completed
Phase	Phase 4
Start date	January 1, 2010
Completion date	December 31, 2016

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02287649` - Polymorphism and Auto-reactive B and T Cells Subsets in Adult's Immune Thrombocytopenia (ITP)	N/A
Completed	`NCT02556814` - Caffeic Acid Combining High-dose Dexamethasone in Management of ITP	Phase 4
Terminated	`NCT02401061` - PRTX-100-202 Open-Label, Dose Escalation Study in Adult Patients With ITP	Phase 1/Phase 2
Completed	`NCT02868099` - Efficacy and Safety of Romiplostim in Adult Subjects With Persistent or Chronic Immune Thrombocytopenia (ITP)	Phase 3
Completed	`NCT02351622` - Caffeic Acid Tablets as a Second-line Therapy for ITP	Phase 3
Active, not recruiting	`NCT04741139` - Post IVIG Medication in Children With Immune Thrombocytopenia	Phase 1
Not yet recruiting	`NCT05468866` - The Expression of Immune Checkpoint CD28 rs1980422-related Single-nucleotide Polymorphisms in the Primary Immune Thrombocytopenia	N/A
Not yet recruiting	`NCT05494307` - The Combination of Terbutaline and Danazol as the Treatment of Corticosteroid-resistant/Relapse Immune Thrombocytopenia	Phase 2
Recruiting	`NCT05281068` - The Combination of Iguratimod and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia	Phase 2
Recruiting	`NCT04993885` - Avatrombopag in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies	Phase 2
Not yet recruiting	`NCT05020288` - A Clinical Trial of the Orelabrutinib in the Management of Refractory ITP	Phase 2
Withdrawn	`NCT03965624` - Efficacy and Safety of Ixazomib and Dexamethasone Refractory Autoimmune Cytopenia	Phase 2
Not yet recruiting	`NCT03252457` - Decitabine Combining Dexamethasone Versus Dexamethasone in Management of ITP	Phase 3
Recruiting	`NCT05937828` - OBS'CEREVANCE: French Cohort of Pediatric Autoimmune Cytopenia
Completed	`NCT03156452` - Newly Diagnosed Immune Thrombocytopenia Testing the Standard Steroid Treatment Against Combined Steroid & Mycophenolate	Phase 3
Completed	`NCT03164915` - A Clinical Study to Evaluate the Efficacy and Safety of LIV-GAMMA SN Inj. in Primary Immune Thrombocytopenia (ITP)	Phase 3
Recruiting	`NCT02270801` - Recombinant Human Thrombopoietin (rhTPO) in Management of Immune Thrombocytopenia (ITP) in Pregnancy	Phase 3
Withdrawn	`NCT01976195` - High-dose Dexamethasone Combining Thalidomide Versus Dexamethasone Mono-therapy for Management of Newly-diagnosed ITP	Phase 2
Completed	`NCT01933035` - Extended Platelet Parameters as a Means to Differentiate Immune Thrombocytopenia From Hypo-proliferative Thrombocytopenias.	N/A
Recruiting	`NCT02821572` - Role of Fcgamma Receptors in Immune Thrombocytopenia (ITP)